[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352747-105":59,"doc-detail-352747-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","propofol-regulates-mettl3-mediated-parp-1-m6a-modification-to-promote-parthanatos-to-improve-nsclc-chemotherapy-resistance","Propofol regulates METTL3-mediated PARP-1 m6A modification to promote Parthanatos to improve NSCLC chemotherapy resistance","","Propofol enhances chemosensitivity in non-small cell lung cancer (NSCLC) by promoting Parthanatos. In NSCLC cell and nude-mouse models treated with cisplatin, propofol increases apoptosis-inducing factor (AIF) and macrophage migration inhibitory factor (MIF) binding and nuclear translocation, triggers loss of mitochondrial membrane potential, NAD+ depletion and PAR accumulation, and elevates DNA damage marker γH2AX. Propofol also raises IL-6 levels. Mechanistically, METTL3 overexpression increases PARP-1 m6A modification and Parthanatos activation, while METTL3 knockdown reverses these effects, restoring cisplatin resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/propofol-regulates-mettl3-mediated-parp-1-m6a-modification-to-promote-parthanatos-to-improve-nsclc-chemotherapy-resistance/352747/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/propofol-regulates-mettl3-mediated-parp-1-m6a-modification-to-promote-parthanatos-to-improve-nsclc-chemotherapy-resistance/352747.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does propofol improve cisplatin chemosensitivity in NSCLC?","Question",{"text":112,"@type":113},"Propofol promotes Parthanatos, leading to increased DNA damage signaling (γH2AX), mitochondrial dysfunction, NAD+ depletion, PAR accumulation, and AIF/MIF nuclear translocation, which sensitizes NSCLC cells to cisplatin.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular pathway links METTL3 to PARP-1 and Parthanatos?",{"text":117,"@type":113},"METTL3 overexpression enhances PARP-1 m6A modification and activates Parthanatos, whereas METTL3 knockdown produces the opposite effect, reducing Parthanatos-driven cell death.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports Parthanatos as the mechanism rather than only apoptosis?",{"text":121,"@type":113},"The study reports Parthanatos-characteristic markers and processes, including AIF involvement, NAD+ depletion, PAR accumulation, mitochondrial membrane potential loss, and extensive DNA fragmentation alongside γH2AX upregulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352747,1790132280,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPropofol regulates METTL3-mediated PARP-1 m6A modification to promote Parthanatos to improve NSCLC chemotherapy resistance  \nQuan Ling, Kepeng Liu, Junlin Wen, Jin Liu & Yong Chen􀀍  \nThis study aimed to investigate the molecular mechanism by which propofol enhanceschemosensitivity in non-small cell lung cancer (NSCLC). In vitro experiments were performed to evaluate the effects of propofol on NSCLC cell lines and to elucidate the underlying molecular mechanisms. In vivo, A549/DDP cells were subcutaneously injected into nude mice, followed by cisplatin (DDP) treatment, and tumor tissues were subsequently analyzed by hematoxylin–  \neosin staining and immunohistochemistry. Our results demonstrated that propofol significantly enhanced the sensitivity of A549/DDP cells to cisplatin by promoting Parthanatos. This process was characterized by increased apoptosis-inducing factor (AIF) and macrophage migration inhibitory factor (MIF) binding and nuclear translocation, loss of mitochondrial membrane potential, nicotinamide adenine dinucleotide (NAD+ ) depletion, accumulation of poly(ADP-ribose) (PAR), and increased expression of the DNA damage marker phosphorylated histone H2AX (γH2AX). Moreover, propofol treatment was associated with elevated interleukin-6 (IL-6) levels. Mechanistically, overexpression of methyltransferase-like 3 (METTL3) enhanced PARP-1 m6A modification and Parthanatos activation, whereas METTL3 knockdown exerted the opposite effects. Furthermore, propofol enhanced cisplatinsensitivity by regulating METTL3-mediated m6A modification of PARP-1 in vitro, which was further confirmed in vivo. In conclusion, propofol enhances cisplatin chemosensitivity in NSCLC by activating Parthanatos through modulation of METTL3-mediated PARP-1 m6A modification. These findings provide mechanistic insight into propofol-mediated reversal of chemoresistance and identify the METTL3–PARP-1–Parthanatos axis as a potential therapeutic target in NSCLC.  \nKeywords Non-small cell lung cancer, Propofol, PARP-1, m6A, Parthanatos, Chemotherapy resistance  \nGlobally, lung cancer ranks as the most common cancer and stands as a leading cause of cancer-related deaths1. According to the most recent global cancer statistics, lung cancer remains the leading cause of cancer-related mortality worldwide, with persistently poor long-term survival outcomes2,3. NSCLC accounts for 85% of all lung cancer instances. Presently, NSCLC treatment protocols encompass surgical procedures, radiotherapy, chemotherapy, specialized targeted therapies, or a mix of these methods4. NSCLC patients exhibit the most severe morbidity and mortality rates compared to other malignant tumors, with their five-year overall survival rate falling below 20%5,6. Advancements in clinical diagnosis and treatment methods have eased the management of NSCLC, but patient survival rates are still less than ideal, owing to distinct physiological states and common drug resistance. Lung cancer chemoresistance represents a significant challenge in clinical treatment failure and recurrence, and the emergence of drug resistance is a complex process involving multiple factors and genetic alterations and signaling pathways. Therefore, clarifying the precise molecular underpinnings of NSCLC drug resistance, identifying novel action targets, and creating potent, low-toxicity counteracting agents along with suitable chemotherapy approaches will lead to fresh concepts and tactics for NSCLC therapy.  \nIn the treatment of NSCLC, propofol is a commonly used intravenous anesthetic. Recent studies have revealed its possible anti-tumor effect. Especially in inhibiting tumor growth and metastasis, propofol has shown potential therapeutic value. For example, a study found that propofol inhibited the proliferation and promoted the apoptosis of NSCLC cells in vitro and in vivo by regulating the microribonucleic acid-21 (miR- 21)/chromosome 10","cbCaipFRSnuulZ1r","https://ap.wps.com/l/cbCaipFRSnuulZ1r","pdf",4373934,13,"English","# Introduction\n## NSCLC burden and chemotherapy resistance\n## Propofol as an anesthetic with anti-tumor potential\n# Mechanistic background\n## Parthanatos mediated by PARP-1\n# Study design and results\n## Effects of propofol on cisplatin sensitivity\n## METTL3-mediated m6A modification of PARP-1 and Parthanatos activation","[{\"question\":\"How does propofol improve cisplatin chemosensitivity in NSCLC?\",\"answer\":\"Propofol promotes Parthanatos, leading to increased DNA damage signaling (γH2AX), mitochondrial dysfunction, NAD+ depletion, PAR accumulation, and AIF/MIF nuclear translocation, which sensitizes NSCLC cells to cisplatin.\"},{\"question\":\"What molecular pathway links METTL3 to PARP-1 and Parthanatos?\",\"answer\":\"METTL3 overexpression enhances PARP-1 m6A modification and activates Parthanatos, whereas METTL3 knockdown produces the opposite effect, reducing Parthanatos-driven cell death.\"},{\"question\":\"What evidence supports Parthanatos as the mechanism rather than only apoptosis?\",\"answer\":\"The study reports Parthanatos-characteristic markers and processes, including AIF involvement, NAD+ depletion, PAR accumulation, mitochondrial membrane potential loss, and extensive DNA fragmentation alongside γH2AX upregulation.\"}]","Propofol regulates METTL3-mediated PARP-1 m6A modification to promote Parthanatos to improve NSCLC chemotherapy resistance | PDF",1790101215,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac3fdad3abd31b42af9d80849b453d6f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/400856378bbd3d65e31a9f77548ad76f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6e049468abb9c945e585fb52f5efd53.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06cb57cea445c1b32354f9cd643289ee.webp",980,1287]